Background-Cardiac-targeted expression of truncated K v 4.2 subunit (K v 4.2N) reduces transient outward current (I to ) density, prolongs action potentials (APs), and enhances contractility in 3-to 4-week-old transgenic mice. By 13 to 15 weeks of age, these mice develop severely impaired cardiac function and signs of heart failure. In this study, we examined whether augmented contractility in K v 4.2N mice results from elevations in intracellular calcium ([Ca 2ϩ ] i ) secondary to AP prolongation and investigated the putative roles of calcineurin activation in heart disease development of K v 4.2N mice. Methods and Results-At 3 to 4 weeks of age, L-type Ca 2ϩ influx and peak [Ca 2ϩ ] i were significantly elevated in K v 4.2N myocytes compared with control because of AP prolongation. Cardiac calcineurin activity was also significantly elevated in K v 4.2N mice by 5 weeks of age relative to controls and increased progressively as heart disease developed. This was associated with activation of protein kinase C (PKC)-␣ and PKC-but not PKC-⑀, as well as increases in ␤-myosin heavy chain (␤-MHC) and reductions in sarcoplasmic/endoplasmic reticulum Ca 2ϩ -ATPase (SERCA)-2a expression. Treatment with either cyclosporin A or verapamil prevented increases in heart weight to body weight ratios, interstitial fibrosis, impaired contractility, PKC activation, and changes in the expression patterns of ␤-MHC and SERCA2a.
T he cardiac Ca 2ϩ -independent transient outward current (I to ) is encoded by K v 4.2, K v 4.3, and K v 1.4 genes. 1 Reduction in I to , as typically occurs in heart disease, results in prolongation of the early phase of the cardiac action potential (AP). 2 Electrophysiological consequences of increased AP duration in heart disease include QT prolongation 3 and increased arrhythmias. 4 Indeed, reduced K ϩ currents in transgenic mice can cause AP prolongation, [5] [6] [7] lengthened QT intervals, and ventricular tachyarrhythmias. 5, 7 AP prolongation as a result of I to reduction in rodent hearts also elevates intracellular Ca 2ϩ transients via increased L-type Ca 2ϩ influx (I Ca,L ), 8, 9 thereby leading to enhanced myocardial contractility. The finding that I to downregulation and associated AP prolongation occur early in the disease process 10 suggests that this may represent a compensatory mechanism to enhance contractility of the compromised myocardium. 11 In addition to enhancing contractility, increased Ca 2ϩ entry via I Ca,L after AP prolongation might also contribute to the myocyte hypertrophy commonly seen in heart disease by acting as a stimulus for cellular growth through the activation of cell-signaling pathways, 11 such as the calcineurindependent pathway 12 or the interconnected protein kinase C (PKC)-␣-dependent pathway. 13, 14 Recently, this Ca 2ϩ hypothesis was directly supported in mice overexpressing the L-type Ca 2ϩ channel in the heart, in which a sustained increase in I Ca,L resulted in severe cardiomyopathy by 8 months of age via PKC-␣ activation. 13 Previously, we showed that overexpressing an N-terminal fragment of K v 4.2 (K v 4.2N) reduced I to and prolonged APs in transgenic mice in a dominant-negative manner. 6 The hearts of K v 4.2N mice were hypercontractile at 2 to 4 weeks of age and progressively developed cardiac hypertrophy with cham-ber dilatation by 13 to 15 weeks of age. In this study, we demonstrate that reductions in I to and resultant AP prolongation enhance both transsarcolemmal Ca 2ϩ influx and intracellular Ca 2ϩ in K v 4.2N myocytes. Furthermore, the transition from hypercontractility to cardiomyopathy in K v 4.2N hearts can be prevented by either Ca 2ϩ channel blockade or calcineurin inhibition, supporting the notion that aberrant Ca 2ϩ cycling leading to activation of calcineurin may contribute to the initiation of heart disease.
Methods

K v 4.2N Transgenic Mice
Transgenic mice overexpressing a truncated K v 4.2 subunit (K v 4.2N) were generated as reported previously. 6 
Cardiomyocyte Isolation
Mouse ventricular myocytes were isolated from 2-to 4-week-old control and transgenic mice as previously described. 6 Electrophysiology and Intracellular Ca 2؉ Measurements
Electrophysiological and intracellular Ca 2ϩ recordings were performed using the whole-cell patch-clamp technique as previously described. 9 For AP and intracellular Ca 2ϩ transient measurements, the extracellular solution was composed of (mmol/L): 140 NaCl, 4 KCl, 10 HEPES, 1 MgCl 2 , 2 CaCl 2 , and 10 D-glucose, adjusted to pH 7.4 with NaOH. For I Ca,L measurements, the extracellular solution contained (mmol/L): 135 choline-Cl, 10 HEPES, 1 MgCl 2 , 2 CaCl 2 , and 10 D-glucose, adjusted to pH 7.4 with CsOH. The pipette solution for AP measurements contained (mmol/L): 140 KCl, 10 HEPES, 1 MgCl 2 , 10 NaCl, 7 Mg-ATP, and 0.1 BAPTA, adjusted to pH 7.2 with KOH. The same internal solution was used for Ca 2ϩ measurements, but 100 mol/L BAPTA was replaced with 60 mol/L fura 2 pentapotassium salt. Pipette solutions for I Ca,L contained (mmol/L): 120 aspartic acid, 120 CsOH, 10 HEPES, 1 MgCl 2 , 7 Mg-ATP, 10 mmol/L TEA-Cl, and 10 EGTA, adjusted to pH 7.2 with CsOH. APs were evoked in current-clamp mode by a brief 5-ms current injection. Intracellular Ca 2ϩ and I Ca,L were measured with current-clamp and AP-clamp recordings after steady-state stimulation at a frequency of 0.25 Hz.
Calcineurin Activity
Calcineurin phosphatase enzymatic activity was measured in duplicate from cardiac protein extracts obtained from 3 to 5 hearts as described previously. 15 
Treatment Protocol
Male transgenic K v 4.2N mice and littermate controls were divided into 4 groups at 2 to 3 weeks of age for either cyclosporin A (CsA) or verapamil treatment: controlϩvehicle, controlϩCsA (or verapamil), K v 4.2Nϩvehicle, and K v 4.2NϩCsA (or verapamil). The vehicle used for CsA was the castor oil-based solvent cremaphor (Sigma), and for verapamil, 3% dextrose was used. CsA-treated mice were injected once daily subcutaneously with a dose of 30 mg/kg of CsA (Calbiochem), whereas vehicle-treated mice received an equivalent volume of cremaphor. Verapamil (Sigma) was administered through drinking water (0.025 mg/mL). CsA was withdrawn for 48 hours, and verapamil was withdrawn for 24 hours before assessment of ventricular function. Direct effects of CsA on contractile function were assessed in control mice after 4 weeks of treatment without drug withdrawal.
Histology
After each mouse was euthanized, hearts were removed and either snap-frozen in liquid nitrogen for Western analysis or calcineurin assays or fixed in 10% buffered formalin for histopathology. At least 3 hearts from each group were bisected midway between base and apex and embedded in paraffin. Thin sections (5 mol/L) were cut on a rotary microtome and stained with hematoxylin/eosin or elastic trichrome.
Hemodynamic Indexes
Mice were anesthetized with ketamine (50 to 100 mg/kg IP) and xylazine (3 to 6 mg/kg IP). The right common carotid was cannulated with a 1.4F Millar catheter (Millar Inc), which was advanced into the proximal aorta and into the left ventricular cavity. Pressure recordings were filtered at 300 Hz and sampled at 2 kHz (2801A, Data Translation). The time constant for isovolumic relaxation, tau (), was determined by fitting the bottom half of the left ventricular pressure traces with a monoexponential function, P(t)ϭP o e Ϫt/ .
Echocardiography
After anesthesia (see above), transthoracic 2D, M-mode, and Doppler echocardiographic examination was performed with an Acuson Sequoia C256 system equipped with a 15-MHz linear transducer (15L8) (version 4.0, Acuson Corp).
Western Analysis and PKC Translocation
Protein (10 g) from the total homogenates of individual mouse hearts were analyzed by Western blot as previously described 16 with monoclonal antibodies to sarcoplasmic/endoplasmic reticulum Ca 2ϩ -ATPase (SERCA)-2a (Santa Cruz Biotechnology), ␤-myosin heavy chain (␤-MHC) (kindly provided by Dr Jeffery Robbins, Cincinnati, Ohio), and calsequestrin (Santa Cruz Biotechnology), which was used as an internal standard. Membrane and cytosolic fractions of heart homogenates were isolated as previously described. 14 Proteins were separated on an 8% SDS-PAGE and transferred to nitrocellulose membranes. Membranes were stained with Ponceau S to check for equal protein loading and then cut into 2 halves: the upper half was probed with PKC-␣, PKC-, or PKC-⑀ antibodies, and the bottom half was probed with calsequestrin antibody (Santa Cruz Biotechnology), which was used as an internal standard.
Statistical Analysis
A 1-way ANOVA was used to test for overall significance, followed by the Student-Newman-Keuls test for multiple comparison testing between the various groups. The unpaired t test was used to compare the means of 2 groups. All statistical analyses were performed with the SPSS software (version 10.1). A value of PϽ0.05 was considered statistically significant. Data are presented as meanϮSEM; n refers to the sample size. As reported previously, 6 overexpressing a dominant-negative truncated mutant K v 4.2 subunit prolongs AP duration (APD; Figure 1A ) in K v 4.2N myocytes (APD 50,Kv4.2N ϭ9.9Ϯ0.7 ms, APD 90,Kv4.2N ϭ35.2Ϯ5.1 ms; nϭ4) compared with controls (APD 50,CON ϭ3.1Ϯ0.4 ms, APD 90,CON ϭ20.2Ϯ3.6 ms; nϭ8). 6 The increased APD 50 in K v 4.2N myocytes is consistent with the dominant contribution of I to,f to repolarization in mouse myocardium. 17 As expected from previous reports, 9, 18 total Ca 2ϩ entry through L-type Ca 2ϩ channels (Q Ca,L ) was elevated (PϽ0.01) nearly 3-fold in transgenic myocytes (Q Ca,L ϭ14.8Ϯ1.7 picocoulombs, nϭ6) stimulated with typical K v 4.2N APs compared with control myocytes (Q Ca,L ϭ5.1Ϯ0.9 picocoulombs, nϭ7) driven by control APs ( Figure 1B ). Despite these differences in integrated Ca 2ϩ entry per beat, I Ca,L densities evoked by voltage steps to ϩ10 mV did not differ significantly between control (15.9Ϯ1.9 pA/pF, nϭ6) and K v 4.2N (15.2Ϯ1.5 pA/pF, nϭ6) myocytes. These results demonstrate that I Ca,L is highly dependent on AP profile in mouse cardiac myocytes and that AP prolongation in K v 4.2N mice produces large increases in Q Ca,L , independent of changes in L-type Ca 2ϩ channel densities. To determine whether intracellular Ca 2ϩ is also altered in K v 4.2N myocytes, [Ca 2ϩ ] i transients were recorded in myocytes isolated from 3-to 5-week-old mice ( Figure 1C Figure 1D ).
Results
Effects
Role of Calcineurin in K v 4.2N Mice
The above results suggest that cardiac hypercontractility in early-stage K v 4.2N hearts results from AP prolongation and increased Ca 2ϩ influx through I Ca,L . These sustained elevations in [Ca 2ϩ ] i and I Ca,L might also contribute to the transition from hyperfunction to heart failure in the K v 4.2N mice via activation of Ca 2ϩ -dependent signaling pathways. 11 Recently, the Ca 2ϩ -activated phosphatase calcineurin has been identified as an important signaling protein for the induction of hypertrophy in numerous animal models 19, 20 as well as in humans. 21 Therefore, calcineurin activity was measured in both control and K v 4.2N mice before (5 to 8 weeks of age) and after (13 to 15 weeks of age) the development of overt heart disease in the K v 4.2N mice. Figure 2 , A through C, shows that the calcineurin activity is elevated in K v 4.2N hearts, precedes disease development, and increases progressively (PϽ0.05) with age. To establish a causal relationship between calcineurin activation and disease initiation, K v 4.2N mice were treated with the calcineurin inhibitor CsA for 12 weeks beginning at 3 weeks of age. Figure 3A shows that calcineurin inhibition effectively reduced (PϽ0.05) the ratio of heart weight (HW) to body weight (BW) of K v 4.2N mice (HW/BW Kv4.2N,Veh ϭ0.57Ϯ0.06, nϭ10; HW/ BW Kv4.2N,CsA ϭ0.44Ϯ0.02, nϭ8) to control levels. Furthermore, treatment with CsA did not affect body weight in either control or K v 4.2N mice (data not shown).
Trichrome staining shows that extensive cardiomyocyte vacuolization and interstitial fibrosis accompany myocyte hypertrophy as assessed by cell-membrane capacitance (232Ϯ16 pF; nϭ16) in vehicle-treated 15-week-old K v 4.2N hearts ( Figure 4B ) compared with vehicle-treated controls (156Ϯ6 pF; nϭ23; Figure 4A ). The causes of the excessive collagen deposition in late-stage K v 4.2N hearts are unclear but are consistent with myocyte dropout, 6 potentially arising from calcineurin-dependent apoptosis. 22 By contrast, CsA treatment of K v 4.2N mice markedly reduced these pathological changes ( Figure 4C ). Functional characterization of hearts from 13-to 15-weekold vehicle-treated and CsA-treated K v 4.2N mice showed that systolic and diastolic ventricular function was significantly improved with CsA treatment. In fact, fractional shortening, heart-rate-corrected velocity of fractional shortening (Table  1) , and ϩdP/dt (Table 2) were all enhanced (PϽ0.05) relative to control, as observed in untreated K v 4.2N mice before the onset of pathology. These findings did not appear to result from direct effects of CsA, because CsA treatment reduced contractility in 7-week-old control mice, consistent with previous findings, 23 whereas K v 4.2N treated with CsA mice at this age remained hypercontractile (data not shown). These results demonstrate that enhanced ventricular function in 13-to 15-week-old, CsA-treated K v 4.2N mice reflects a genuine hypercontractility, probably arising from AP prolongation. Although diastolic function was not enhanced in CsA-treated K v 4.2N mice, normalization of the passive versus active components of mitral flow (E/A ratios), 24 as well as restoration of ϪdP/dt and rate of ventricular pressure decay () (Tables 1 and 2 ), collectively suggest that normal diastolic function was preserved in CsA-treated K v 4.2N mice.
Effects of Verapamil Treatment on Cardiac Morphology and Ventricular Function
Having established that calcineurin activation is critical for disease progression in K v 4.2N mice, we next tested whether the heart disease process depended on I Ca,L . Because the total integrated I Ca,L (Q Ca,L ) is increased Ϸ3-fold as a result of AP prolongation in K v 4.2N myocytes and because the activity of numerous hypertrophic signaling pathways, including the calcineurin pathway, are Ca 2ϩ -dependent, 25 we examined whether treatment of K v 4.2N mice with L-type Ca 2ϩ channel blockers could modify the course of the disease. As seen with CsA, verapamil treatment also normalized HW/BW ratios (HW/BW Kv4.2N-Veh ϭ0.51Ϯ0.03, nϭ6; HW/BW Kv4.2N-Verap ϭ 0.35Ϯ0.02, nϭ8; HW/BW CON,Veh ϭ0.38Ϯ0.01) ( Figure 3B ) and improved the cardiac morphology of K v 4.2N mice by reducing interstitial fibrosis and cardiomyocyte vacuolization ( Figure 4D ) compared with vehicle-treated K v 4.2N hearts ( Figure 4B ).
Both systolic and diastolic ventricular function as assessed by echocardiographic and hemodynamic measures (Tables 1  and 2) were also restored to control levels in verapamil- 
Expression of SERCA2a and ␤-MHC and PKC Activation
Reduced expression of SERCA2a and enhanced expression of ␤-MHC are universal molecular markers of cardiac dysfunction and disease ( Figure 5 ). 26, 27 Figure 5A and 5B Figure 5A and 5C). Because calcineurin activation is associated with a characteristic pattern of PKC isoform activation, 14 the membrane translocation patterns of the PKC-␣, -⑀, and -isoforms were examined. The membrane-to-cytosol ratios of the PKC-␣ and PKC-isoforms were increased 6.1-and 2.4-fold, respectively, in K v 4.2N mice relative to controls ( Figure 6 , A through C). Consistent with a connection between PKC and calcineurin pathways, treatment of K v 4.2N mice with either verapamil or CsA normalized both PKC-␣ and -expression patterns ( Figure 6, A through C) . In contrast, PKC-⑀ activation did not differ among any of the groups studied ( Figure 6 , A and D).
Discussion
Diminished I to density and altered AP profile have been associated with heart disease in humans and in numerous animal models. 1, 2, 18, 28 This I to reduction occurs early in the disease process, 10 suggesting that I to may play a role in the initiation of disease. 11 Previously, we found that primary I to reduction achieved by cardiac-restricted overexpression of a truncated K v 4.2N peptide in mice causes enhanced ventricular function that progresses to failure by 15 weeks of age. 6 In this study, we investigated the potential role of Ca 2ϩ in the enhanced contractility and progression of disease in K v 4.2N overexpressing mice.
Consistent with previous studies in rat myocytes, 8,9,18 AP prolongation in K v 4.2N transgenic myocytes increased peak [Ca 2ϩ ] i , supporting the notion that I to plays an important role in influencing Ca 2ϩ handling and contractility in situations, such as heart disease, in which I to densities are reduced. 8, 9, 18 Our results are the first to demonstrate enhanced Ca 2ϩ transients and inotropy via altered AP profile in transgenic mice with selective I to reductions. Associated with elevated intracellular Ca 2ϩ , calcineurin activity increased with disease progression, consistent with previous studies establishing a central role for calcineurin activation in animal models of cardiac hypertrophy 12, 19, 20 and during the hypertrophic phase of human heart disease. 21 The finding that calcineurin activity was elevated in K v 4.2N mice before the onset of disease prompted us to attempt to prevent disease development by inhibiting I Ca,L or calcineurin. The high degree of protection conferred to K v 4.2N transgenic mice by verapamil or CsA suggests that the transition from hyperfunction to failure in K v 4.2N mice is Ca 2ϩ -dependent. Recently, Muth et al 13, 29 showed that cardiac-specific overexpression of voltage-dependent L-type Ca 2ϩ channels (L-VDCCs) resulted in increased Ca 2ϩ influx and enhanced basal contractility in mice at 8 weeks of age 29 and progression to cardiomyopathy by 8 months of age. 13 The striking similarity in activation of signaling pathways and overall phenotype between the L-VDCCs and the K v 4.2N mice suggests common mechanisms. Indeed, both transgenic models generate chronically elevated I Ca,L (by 50% in L-VDCC mice 13 and by 200% in K v 4.2N mice) and show activation of Ca 2ϩ -dependent PKC-␣ but not PKC-⑀. Although calcineurin signaling was not examined in L-VDCC mice, 13 calcineurin activation has recently been associated with a characteristic activation profile of PKC isoforms (PKC-␣ and -and not -⑀, -␤, or -) and mitogen-activated protein kinase signaling pathways (JNK and not p38 or ERK1/2). 14 The patterns of PKC isoform activation observed in our studies in association with calcineurin activation are consistent with these findings and suggest that the calcineurin pathway is the dominant hypertrophic signaling pathway in K v 4.2N mice.
Regardless of the specific hypertrophic signaling pathways involved, the phenotypes observed in both K v 4.2N and L-VDCC transgenic mice implicate Ca 2ϩ -dependent mechanisms. 11 These observations may be clinically relevant, because the initial stage of heart disease is typically characterized by I to downregulation 2,10 and neurohumoral activation, 30 both of which may elevate Ca 2ϩ influx and intracellular Ca 2ϩ , thereby helping to maintain adequate cardiac output from the diseased heart. Our results suggest that normalization of Ca 2ϩ cycling via I Ca,L blockade or decoupling of the beneficial inotropic effects of Ca 2ϩ from its detrimental hypertrophic effects via inhibition of Ca 2ϩ -dependent signaling pathways may present a useful therapeutic strategy for heart disease treatment.
Interestingly, the absence of cardiac pathology in the phospholamban knockout mouse, which also exhibits elevated intracellular [Ca 2ϩ ] i via enhancements in SR Ca 2ϩ uptake, 31 suggests that the source of the Ca 2ϩ imbalance (I Ca,L versus SERCA2a:phospholamban ratio) might be an important factor in disease initiation. The subsarcolemmal colocalization of calcineurin 32 and PKC with the L-type Ca 2ϩ channel via the A-kinase anchoring protein AKAP79 33 supports the notion that these molecules may respond preferentially to local elevations in submembrane Ca 2ϩ , as expected after enhancements in I Ca,L versus bulk cytosolic Ca 2ϩ . The discrepancy in the phenotypes observed in the K v 4.2N and K v 4.2W362F mice, 7 despite similar electrophysiological findings, suggests that secondary effects of K v 4.2N peptide expression, 6 in addition to enhanced Ca 2ϩ cycling, may contribute in part to the cardiomyopathy in K v 4.2N mice. Recent studies in our laboratory, however, have demonstrated that overexpression of either K v 4.2N or K v 4.2W362F transgenes in neonatal rat ventricular myocytes both result in similar levels of Ca 2ϩ -calcineurin-dependent hypertrophy. 34 Furthermore, consistent with our findings, additional studies have now revealed that pressure-overload-induced cardiac hypertrophy is enhanced in K v 4.2W362FxKv1.4
Ϫ/Ϫ mice relative to controls, 35 suggesting that I to reduction and AP prolongation do, in fact, contribute to myocyte hypertrophy.
In summary, we have shown that AP prolongation as a result of I to reduction by overexpression of the K v 4.2N peptide increases contractility in early-stage transgenic myocytes by increasing I Ca,L and intracellular [Ca 2ϩ ] i . Progression to failure then occurs via a Ca 2ϩ -and calcineurin-dependent process that is associated with activation of PKC-␣ and -but not -⑀ and can be inhibited by verapamil and CsA. Although a secondary, indirect effect of K v 4.2N expression may also contribute to disease in these hearts, our data clearly show that I Ca,L , [Ca 2ϩ ] i , and calcineurin are dominant players in the pathology observed after AP prolongation in K v 4.2N hearts. Furthermore, these findings are consistent with a "Ca 2ϩ hypothesis" of hypertrophic gene expression induced by sustained elevations in Ca 2ϩ influx and/or intracellular [Ca 2ϩ ] i .
